// App-Quantinova.ai

3588 : Phase I Trial of Belinostat and Bortezomib in Patients with Relapsed or Refractory Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia in Blast Crisis - One Year Update

Researchers

Presenter

  • Prithviraj Bose

Principal Investigators

  • Mary Beth Tombes

  • Steven Grant

  • Ellen Shrader

  • Wen Wan

  • Caryn Weir-Wiggins

  • Elizabeth Stoddert

  • Heidi Sankala

  • Maciej Kmieciak

  • John D. Roberts

  • Guillermo Garcia-Manero

Medical Centers

  • Virginia Commonwealth University Medical Center, Richmond, VA

  • Virginia Commonwealth University Medical Center, Richmond, VA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic myelomonocytic leukemia

  • Peripheral neuropathy

  • Chronic Myelogenous Leukemia

  • Acute lymphoblastic leukemia

  • Alpha-thalassemia myelodysplasia syndrome

  • Ischemic stroke

  • Acute myelocytic leukemia

  • B cell lymphomas

  • Thrombocytopenia

  • Acute Leukemia

  • Lymphomas

  • Multiple Myeloma

Biomarkers

  • B-cell lymphoma-extra large

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • X-linked inhibitor of apoptosis

Drug/Treatment

  • belinostat Intravenous

  • Bortezomib

  • PXD101

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved